Cargando…
Comment on “Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status“
Autores principales: | Pappagallo, Marco, Inturrisi, Charles E., Manfredi, Paolo L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863724/ https://www.ncbi.nlm.nih.gov/pubmed/35015265 http://dx.doi.org/10.1007/s40263-021-00891-0 |
Ejemplares similares
-
Novel glutamatergic drugs for the treatment of mood disorders
por: Lapidus, Kyle AB, et al.
Publicado: (2013) -
Disturbance of the Glutamatergic System in Mood Disorders
por: Jun, Chansoo, et al.
Publicado: (2014) -
Esmethadone (REL-1017) and Other Uncompetitive NMDAR Channel Blockers May Improve Mood Disorders via Modulation of Synaptic Kinase-Mediated Signaling
por: Stahl, Stephen M., et al.
Publicado: (2022) -
Extracorporeal membrane oxygenation in pregnancy: details on novel therapies and cardiac, preeclampsia, and mood disorder complications
por: Yin, Ophelia, et al.
Publicado: (2022) -
Organic mood disorder: Sequelae of small vessel disease
por: Shejekar, Shradha, et al.
Publicado: (2019)